Cooper and other state attorneys general alleged that the drug manufacturer engaged in deceptive practices by misrepresenting the cardiovascular risks for those who took the drug.
North Carolina will receive $2,673,740 for consumer protection purposes. Cooper also recovered $400,000 for the State Health Plan.
In 2010, a panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. Panelists who voted to keep the drug on the market were split between several options, including adding new warning labels and restricting use of the drug.
In the settlement, Glaxo also agreed to reform how it markets and promotes diabetes drugs.